Leishmania surface glycocalyx

The Leishmania surface glycocalyx is a dense, complex layer of glycoconjugates that coats the surface of Leishmania parasites, playing a critical role in their survival and pathogenicity [1]. Its primary components include lipophosphoglycan (LPG), glycosylphosphatidylinositol (GPI)-anchored proteins like gp63 (leishmanolysin), and glycoinositolphospholipids (GIPLs) [2]. This structure serves as a protective shield against the host's hydrolytic enzymes and complement-mediated lysis while facilitating the parasite's attachment to the sandfly midgut and subsequent entry into host macrophages [3]. In the host, the glycocalyx modulates immune signaling, often suppressing the oxidative burst and pro-inflammatory cytokine production to ensure intracellular survival [4]. Because of its essential role in the parasite life cycle and its unique biochemical composition compared to host cells, the glycocalyx and its biosynthetic pathways are major targets for anti-leishmanial drug development and vaccine candidates [5]. Current treatments like miltefosine and amphotericin B indirectly or directly impact the integrity and composition of this surface coat, though resistance and toxicity remain significant challenges [6]. References: [1] Descoteaux A, Turco SJ. Biochim Biophys Acta. 1999;1455(2-3):453-462. [2] Yao C. Int J Parasitol. 2010;40(2):231-238. [3] Sacks DL, Kamhawi S. Annu Rev Microbiol. 2001;55:453-483. [4] Lodge R, Descoteaux A. Phagocytosis of Bacteria and Protozoa. 2008. [5] Späth GF, et al. Proc Natl Acad Sci U S A. 2003;100(16):9536-9541. [6] Croft SL, Coombs GH. Trends Parasitol. 2003;19(11):502-508.

Other names

Lipophosphoglycan (LPG)Leishmania surface coatPromastigote surface antigen (PSA)gp63 (Leishmanolysin)Glycoinositolphospholipids (GIPLs)

Inhibition of glycoconjugate biosynthesis, disruption of membrane integrity, and interference with lipid metabolism essential for glycocalyx assembly [1, 6].